GLOW blend (GHK-Cu + BPC-157 + TB-500): research

GLOW blend (GHK-Cu + BPC-157 + TB-500) dosage

Typical reported dose: 2 mg GHK-Cu plus 0.4 mg each of BPC-157 and TB-500 once a day

• Daily reports, measured by GHK-Cu: 2.8 mg total: GHK-Cu 2 mg + BPC-157 0.4 mg + TB-500 0.4 mg daily. once daily, under the skin. Reported by users, occasional report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
• A lower-dose 50:10:10 plan: About 2.33 mg total: GHK-Cu 1.67 mg + BPC-157 0.333 mg + TB-500 0.333 mg daily. once daily, under the skin. Reported by users, rare report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
• Muscle-injection report, 40:10:10: 5 mg total daily from a GHK-Cu:BPC:TB ratio of 40:10:10. once daily, into muscle. Reported by users, rare report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

GLOW blend (GHK-Cu + BPC-157 + TB-500) side effects and risks

Reported side effects

• Injection-site pain, redness or swelling: No reliable blend event rate; reports lack a denominator., moderate. Pause for persistent reactions; spreading heat or redness needs prompt assessment. (source)
• Serious allergic or immune reaction: FDA flags immune reaction risk; blend incidence is unknown., serious. Breathing trouble, throat swelling or collapse needs emergency care. (source)
• Infection from a contaminated injection: Product related risk; no measured blend rate., serious. Seek urgent care for fever with spreading redness or severe injection-site pain. (source)
• Fatigue or brain fog: One post describes two users also taking semaglutide; no causal link or population rate., moderate. Review other causes; the report does not prove copper poisoning. (source)

Stop and get help if

• Trouble breathing, throat swelling, collapse or fainting after an injection: Stop and call emergency services now.
• Hot, painful, spreading redness or swelling at an injection site: Stop injections and seek urgent same-day care; fever, confusion or fast breathing needs emergency care.

Who should avoid it

• pregnant: Precaution: no blend pregnancy safety data; pregnancy was excluded from the knee report.
• breastfeeding: Precaution: milk transfer and infant effects have not been studied for the blend.
• tryingToConceive: Precaution: reproductive safety and a safe washout period are unknown.
• under18: Precaution: no pediatric blend safety or dosing studies found.
• activeCancer: Precaution: ingredients promote blood-vessel growth in lab studies; effects on human tumors are unknown.
• cancerHistory: Review prior cancer with the treating clinician; long-term tumor effects have not been measured.
• kidneyDisease: Blend clearance and dose changes in kidney disease are unknown.
• liverDisease: Blend clearance and dose changes in liver disease are unknown.
• bleedingDisorder: Precaution for needle-related bruising and bleeding, especially with muscle injection.
• surgeryPlanned: Tell the surgical team about all ingredients; no safe perioperative stopping interval is established.
• testedAthlete: BPC-157 and TB-500 are prohibited at all times under the 2026 WADA list.
• other: Avoid re-exposure after a serious reaction; peptide impurities can trigger immune reactions.
• other: Precaution: GHK-Cu adds copper exposure; copper buildup can damage organs. No safe injectable blend dose is established.

Interactions

• Duplicate peptide products: Amounts add across vials and blends. No combination study establishes a safe total exposure.
• Oral anticoagulants: Muscle injections can increase bleeding or bruising. This is a needle-related risk; a chemical interaction with the blend is untested.
• Copper-containing supplements: Added copper may matter, especially in copper-handling disease. No safe combined exposure with injected GHK-Cu is established.

Product quality risks

• Label names may hide different TB4 molecules; fragment and full-length products are not interchangeable.
• FDA-reviewed ingredient COAs lacked some content, aggregate or endotoxin controls. HPLC purity alone cannot establish injection safety.
• Unauthorized injections may have wrong amounts, undeclared ingredients, microbes or endotoxins; blend defect rates are unknown.

How GLOW blend (GHK-Cu + BPC-157 + TB-500) works

The proposed idea combines copper-linked repair signals with BPC-157 and TB4-related signals. Ingredient studies suggest changes in collagen, blood vessels and cell movement. No experiment in people shows that this trio works together or that mixing improves results.

• GHK-Cu: connective-tissue remodeling: Increased collagen and other repair material in rat wound chambers.
• BPC-157: vessel-growth signaling: Changed VEGFR2-related signals in animals and cells.
• Full-length TB4: cell movement: Animal wound effects do not validate shorter TB-500 fragments or a mixed vial.

Half-life: Unknown for the blend; no human combination pharmacokinetic study found.